CMS reached its goals for value-based payments in part because of providers’ enthusiasm for new programs, said Kate Goodrich, MD, director of the Quality Measurement and Value-Based Incentives Group in CMS.
CMS reached its 2016 goals for transition to value-based payments early in part because of providers’ enthusiasm for new programs, said Kate Goodrich, MD, director of the Quality Measurement and Value-Based Incentives Group in CMS.
Transcript (slightly modified)
What do you attribute to CMS successfully reaching its 2016 goals for moving to value-based payments 9 months before the deadline?
I think we were able to do this because there have been so many collaborators and partners out there who have been really excited about joining in with the alternative payment models that the Innovation Center had out there. So in the latest few years, we’ve had not only of course the Medicare Shared Savings Program, the three different tracks of that shared savings program, the Pioneer Program which is also an ACO program, as well as our bundled payment programs. And last year we launched the Comprehensive Joint Replacement Model, of course that didn’t go into effect until April of this year so it didn’t have that impact yet.
But I think because we launched a number of models but with tremendous enthusiasm from in particular the provider community, but also from other payers who really wanted to join in with us in aligning the incentives for clinicians in practice, we were really able to leverage that enthusiasm to be successful with the 30 percent goal, as you stated, much earlier than we anticipated.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More